Archive

February 2025

Browsing

A prominent crypto expert has issued a Bitcoin Crash Prediction. He believes that the leading cryptocurrency may soon face a severe crash. His forecast comes amid rising market volatility and shifting investor sentiment.

First, global economic uncertainty is growing. Many investors are cautious because of regulatory pressures and economic slowdowns. In addition, market rumors have intensified fears. Furthermore, price swings have become more frequent. As a result, the crypto market is under increased pressure.

Next, the expert explains that several factors contribute to his prediction. For instance, tighter regulations in key markets have unsettled investors. Moreover, recent policy changes have added to market jitters. In turn, these developments have increased the likelihood of a sudden downturn. Therefore, the expert advises that caution is necessary.

Additionally, technical indicators signal potential trouble. Short-term trends show unusual price drops, while long-term charts reveal instability. Also, trading volumes have been unpredictable. Consequently, these signs may indicate that a crash is on the horizon.

Furthermore, market experts stress the importance of preparedness. They recommend that investors review their portfolios and diversify their assets to reduce exposure to high volatility. In summary, being proactive can help mitigate risks and protect investments.

In conclusion, Bitcoin Crash Prediction is based on several observable factors. Although such predictions are not uncommon in the crypto world, they remind us to stay alert. Overall, the crypto market remains dynamic and uncertain, so investors are encouraged to keep informed and make cautious decisions.

Looking ahead, market participants must monitor trends closely. They should consider expert advice and current technical signals. With rapid changes in the global economy, a crash could occur sooner than expected. Ultimately, the forecast calls for prudence and strategic planning.

Moreover, the prediction has sparked lively discussions among crypto enthusiasts. Many believe that such bold forecasts can drive innovation and encourage industry leaders to invest in new technology. Others, however, warn that the market remains unpredictable and that caution is key. This debate highlights the importance of staying updated on market trends and reassessing strategies regularly.

Conclusion

Overall, while the warning about a Bitcoin crash is based on public observations and technical signals, it serves as a reminder of the volatile nature of cryptocurrencies. Investors should remain vigilant, diversify their portfolios, and prepare for various market scenarios.

The post Bitcoin Crash Prediction, Warns Crypto Expert appeared first on FinanceBrokerage.

Bitcoin attracts bold predictions. Recent forecasts show that this top cryptocurrency may soon hit Bitcoin Reach $200000. Many trusted sources, including Yahoo Finance, CoinDesk, Bloomberg, and CNBC, have reported this forecast. This public news reflects rising optimism among market experts amid changing economic conditions.

Market Sentiment and Economic Drivers

Many analysts believe that economic uncertainty and rising prices create a strong chance for Bitcoin to serve as a safe asset. Investors now see Bitcoin as a reliable store of value. They shift funds to cryptocurrencies when they lose trust in traditional assets. In addition, new regulations in key markets push both large and small investors to spread their money across various assets.

Technical Analysis and Price Trends

Technical data supports a potential price surge. Long-term charts show an upward trend, while short-term drops offer good buying points. Trading volumes and network activity grow each day. Experts point to a limited supply and high demand as key reasons that Bitcoin Reach $200000 upto.

Investor Implications and Risk Management

Investors must stay alert in this volatile market. They should manage risk by diversifying their portfolios. Many experts advise reviewing holdings and allocating funds wisely. They also recommend keeping up with the latest market news and technical signals to guide decisions.

Conclusion

This forecast that Bitcoin may reach $200,000 comes from strong market sentiment, positive technical trends, and a unique economic climate. However, investors face a volatile market that demands caution. Experts urge both individual and institutional investors to monitor these trends closely and prepare for various market moves.

While reaching $200,000 is not guaranteed, this forecast offers valuable insight into the ever-changing crypto market. It shows that the market can shift quickly and that informed decisions are key. Investors should act wisely and stay updated on news and trends. By doing so, they can protect their investments and uncover new opportunities in the fast-paced world of cryptocurrencies.

The post Could Bitcoin Reach $200000? Market & Expert Insights appeared first on FinanceBrokerage.

The US Consumer Confidence Index® came in much lower than expectations, and the Expectations Index fell to 72.9. A fall below 80 signals a recession ahead, enough to elevate the fear of economic weakness. As a result, the stock market sold off. But after 11:30 AM ET, the buyers came in, and the market rebounded from its lows. However, the rebound wasn’t enough to make much of a dent, except for the Dow which closed in the green. 

If you regularly monitor breadth indicators, you may have noticed that the New Highs – New Lows Index ($NYHL) was up over 150%. This caught my attention. The broader equity indexes were falling significantly, yet the new highs were way higher than the new lows. That was unusual, but since the stock market is known for pulling surprises when you least expect it to, it’s helpful to look under the hood to determine if the stock market is strong or weak. 

The Market’s Heart Beat

Looking through the rest of my charts in my Market Analysis ChartList — a part of my daily routine — one that I found interesting is the SPDR S&P 500 ETF (SPY) with the Percent Above Moving Average oscillators in the lower panels (see chart below).

FIGURE 1. DAILY CHART OF SPY. The percentage of S&P 500 stocks trading above their 50-, 100-, and 200-day simple moving averages are above 50 but watch these oscillators closely as they indicate the health of the overall market. Chart source: StockCharts.com. For educational purposes.

It’s interesting to note that the percentage of S&P 500 stocks trading above their 50-, 100-, and 200-day simple moving averages (SMAs) started to decline at the end of September 2024. The SPY was still trending higher and it wasn’t till December when it started to pull back.

The September pullback coincided with a relatively low percentage of stocks trading below their moving averages and declined further during the January 2025 pullback. But the oscillators recovered from these levels and as of now, even though SPY bounced off its 100-day moving average, they are not close to the previous lows. The good thing is they are all above their 50 threshold level. You can’t say the same for the Nasdaq stocks.

The chart below replaces SPY with Invesco QQQ Trust (QQQ) and analyzes the percentage of Nasdaq stocks trading above the 50-, 100-, and 200-day SMAs. They are trading at levels seen in August 2024, which is when QQQ went through a -15.56% pullback.

FIGURE 2. DAILY CHART OF QQQ. Although the QQQ is holding on to the support of its 100-day SMA, the percent of stocks trading below their moving averages are below 50, which is a bearish indication. Chart source: StockCharts.com. For educational purposes.

The Technology sector witnessed a four-day losing streak and was the worst-performing sector in the last week. Tech stocks are facing many headwinds — tariffs, AI unwinding, and chip availability, to name a few. Investors are rotating out of Tech stocks and moving into the offensive sectors — Consumer Staples, Real Estate, and Health Care. 

The Bottom Line

The broader stock market is at an interesting juncture and could go either way. SPY and QQQ are holding on to the support of their 100-day SMA but two important news events could shake things either way — NVIDIA earnings and Personal Consumption Expenditures Price Index (PCE). The rest of the week could be a bumpy ride.

If you haven’t done so, apply the percentage of stocks trading above significant moving averages oscillator. Percentage Above Moving Average indicator is available for several indexes. Try them out and see which ones give you a good “under the hood” look at the broader market.


StockChart Tip. Click the charts of SPY and QQQ in the article to see a live chart.

Then, save the charts to one of your ChartLists. Not sure how to create ChartLists? Check out this tutorial.



Disclaimer: This blog is for educational purposes only and should not be construed as financial advice. The ideas and strategies should never be used without first assessing your own personal and financial situation, or without consulting a financial professional.

Canadian mining industry investment has faced significant challenges over the past decade. There is a common understanding that funding isn’t moving through the sector, especially to juniors.

These small companies represent the foundation for mining in Canada, performing most exploration, and one program that has helped steer investment their way is the federal government’s Mineral Exploration Tax Credit (METC).

The program has been in place for the past two decades, but is set to expire on March 31, 2025.

With parliament prorogued, the mining industry is concerned that the METC will lapse and is calling for its renewal.

What is the Mineral Exploration Tax Credit?

The METC is a 15 percent credit that was created by Canada to help exploration companies raise money. It serves as a supplement to the flow-through share scheme established by the government.

Under the rules established for flow-through shares, companies can shift certain expenses to shareholders.

For tax purposes, these expenses are considered to have been incurred by the investor, not the corporation, and can reduce the investor’s taxable income. Investors in a mining company receive a 100 percent deduction for the amount invested in shares, as well as a 15 or 30 percent credit for eligible expenses.

Individuals who incur eligible exploration expenses pursuant to a flow-through share agreement with a mining company can claim the 15 percent METC. Eligible expenses include prospecting and geological surveys.

The METC applies to investors of all sizes, regardless of their marginal federal income tax rate; however, because some federal flow-through share incentives come in the form of income tax deductions, these deductions can vary.

Mining industry calls for METC extension

In a statement on January 7, the Prospectors & Developers Association of Canada (PDAC) urged members of parliament to renew the METC, calling it one of the federal government’s most productive programs.

‘With exploration investment already in decline, allowing the tax credit to lapse would undermine every segment of Canada’s mineral sector — from coast to coast,’ the organization said.

The PDAC’s release goes on to indicate that the METC is essential to safeguarding Canada’s competitiveness and the resilience of the country’s mining sector as a whole.

The January statement came amid intensifying rhetoric about sweeping US tariffs on Canada and Mexico. The resource sector is a significant exporter to the US, with key products including oil, gas, steel and aluminum.

He said certainty and stability would help maintain Canadian leadership in the resource sector.

“It is one of the most productive Canadian fiscal incentives by delivering a significant return on investment without requiring an outlay of public funds by the federal government,” Goldie noted.

He also spoke about how critical the mining sector is to the Canadian economy, indicating that exploration helps strengthen the country’s economic resilience through economic growth and stronger domestic supply chains.

He noted that minerals add C$100 billion to Canada’s GDP and create hundreds of thousands of jobs.

METC expiration date approaching

In 2018, the METC was extended until March 2024, at which time it was extended until March 31, 2025.

However, given Prime Minister Justin Trudeau’s resignation, the subsequent prorogation of parliament and the Liberal Party’s leadership race, it’s unclear whether the METC will be extended again this time.

The government is scheduled to reconvene on March 24, and given the short time frame between the return of parliament and the expiration of the credit, there are questions around how much will get done.

In addition to the METC, the federal government introduced the Critical Mineral Exploration Tax Credit (CMETC) in 2022. Similar to the METC, it provides a 30 percent credit to support the development of critical mineral projects in Canada that will produce batteries, permanent magnets, clean technology and semiconductors.

The two programs are separate, with the CMETC valid until March 31, 2027.

Securities Disclosure: I, Dean Belder, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

Canyon Resources Limited (ASX: CAY) (‘Canyon’ or the ‘Company’) is pleased to provide an update on key development workstreams at the Company’s flagship Minim Martap Bauxite Project (‘Minim Martap’ or ‘the Project’), located in Cameroon, as the Company continues to make rapid progress toward production.

Minim Martap ranks among the world’s richest bauxite deposits, underpinned by an Ore Reserve of 109Mt at 51.1% total Al2O3 and 2.0% total SiO2 and a JORC Mineral Resource Estimate of 1,027Mt at 45.3% total Al2O3 and 2.7% total SiO2

The Definitive Feasibility Study (DFS) remains on schedule for completion in Q3 2025, with a focus on optimising operational efficiencies, ensuring sustainable economics and confirming the preferred pathway to production. The Company remains confident that the DFS will reinforce the viability of Minim Martap as a world-class bauxite project. Concurrently, discussions with select debt providers are progressing positively, as Canyon seeks to secure an optimal funding structure in alignment with strategic objectives and results from the DFS.

As part of the DFS, Canyon is currently evaluating the implementation of a two-stage development strategy, aimed at accelerating production through a phased ramp-up to enable a first bauxite shipment in 2026. This approach would enable earlier revenue generation, strengthen supply chain relationships and strategically position Minim Martap for future growth as rail capacity expands. In addition to this process, Canyon has engaged several internationally recognised consultants to refine and optimise the existing rail infrastructure required for the transport of the bauxite ore. Detailed assessments are now underway to enhance logistical efficiency and explore capacity expansion strategies that will support long-term operational growth.

As part of project execution planning, Canyon is working with leading mining equipment vendors to define procurement schedules and delivery timelines, ensuring timely access to critical mining equipment, which will be essential for meeting targeted production timelines and targets and maintaining operational efficiency. The Company remains focused on aligning equipment availability with its potential staged development strategy to support seamless project execution.

Discussions with potential offtake partners are advancing well, with negotiations reflecting strong market interest in Minim Martap’s high-quality bauxite product and supporting the Company’s efforts to secure long- term sales agreements. Establishing these strategic partnerships is a key step in de-risking the Project, working through the relevant financing discussions and ensuring an efficient pathway towards commencement of operations.

Bauxite market fundamentals and pricing has strengthened over the past 12 months, with the CIF China price for 45% Al203 and 3% total SiO2 ex Guinea reported to be approximately $US 100/DMT in February 2025. The product from Minim Martap with a proved or reserve grade 51.1% total Al203 and total SiO2 should achieve a considerable premium price compared to a 45% Al2O3 and SiO2 bauxite product.

Lastly, Canyon continues to focus on building out its project team and management team to ensure the Company is well-positioned during the next phase of development growth, as Canyon works toward becoming a near-term bauxite producer.

Mr Jean-Sebastien Boutet, Canyon Chief Executive Officer commented:“Progress at our world-class Minim Martap Project continues as planned, reinforcing our confidence in our timeline towards production. Notably, the analysis of a potential two-staged development strategy has been particularly promising, offering the opportunity for fast-tracked production and revenue generation, while strategically positioning the Company to capitalise on expanding rail capacity and the establishment of key supply chain relationships.

‘Our team remains committed to transforming the Minim Martap Bauxite Project into a world-class operation that delivers sustainable, long-term value for shareholders and stakeholders alike. We will continue to provide timely updates as we achieve key milestones and advance toward production.”


Click here for the full ASX Release

This post appeared first on investingnews.com

In 2024, concern grew about copper supply as copper mines in the top copper-producing countries continued to age without new mines to replace them.

Additionally, copper demand from electrification is expected to rise significantly in the coming years.

The competing forces of the global macroeconomic situation and a tightening supply and demand situation caused major swings in the copper price last year, and the red metal set a new all-time high in May 2024 as it moved above the US$5 per pound mark for the first time.

Despite a tight supply situation, demand from the energy transition has largely been muted as China, traditionally the largest consumer of copper for its infrastructure, works to stimulate its flagging economy.

The forecast for copper over the next few years is that the copper market will move into supply deficits, which in turn should provide more tailwinds for the price of copper and greater upside to company balance sheets.

For investors interested in copper, it’s worth looking at production by country. According to the latest US Geological Survey data, global copper production reached 23 million metric tons (MT) in 2024. Mining output figures for this article were supplemented with data provided by Mining Data Online (MDO).

Chile again took the crown to become the top copper producing country last year, but some of the others on the list may surprise you. Read on to find out the top 10 copper countries and what mines are driving each country’s copper output.

1. Chile

Copper production: 5.3 million metric tons

In 2024, Chile produced 5.3 million metric tons of copper, making it the world’s largest copper producing country with about 23 percent of the total global copper output.

Naturally, many of the world’s leading copper miners have substantial operations in Chile, including the state-owned Codelco, Anglo American (LSE:AAL,OTCQX:AAUKF), Glencore (LSE:GLEN,OTC Pink:GLCNF) and Antofagasta (LSE:ANTO,OTC Pink:ANFGF).

Chile is also home to BHP’s (ASX:BHP,NYSE:BHP,LSE:BHP) Escondida, the largest copper mine in the world. According to BHP’s 2024 annual report, the mine produced 1.13 million metric tons of copper in 2024.

However, Chile’s copper production is expected to rebound to record levels in 2025, according to S&P Global, to hit a projected 6 million MT as new mines ramp up their output.

2. Democratic Republic of Congo

Copper production: 3.3 million metric tons

In 2024, the Democratic Republic of Congo (DRC) produced 3.3 million metric tons of copper, accounting for more than 11 percent of global copper output. The DRC has increased its copper production rapidly in recent years, and its 2024 output marked a significant rise from the 2.93 million metric tons of copper produced the previous year.

One contributor to this increase is Phase 3 of the Ivanhoe Mines (TSX:IVN,OTCQX:IVPAF) Kamoa-Kakula project, which achieved commercial production in August 2024. A joint venture with partner Zijin Mining Group (OTC Pink:ZIJMY,SHA:601899), Kamoa-Kakula produced 437,061 MT of copper in 2024, an increase from the 393,551 MT produced in 2023. Ivanhoe is expecting further increases in production in 2025 and set its guidance for the year at 520,000 and 580,000 MT of copper.

3. Peru

Copper production: 2.6 million metric tons

In 2024, Peru produced 2.6 million metric tons of copper, according to USGS data. The total is down 160,000 MT from its copper output in 2023.

Among the factors impacting the declines was a 3.7 percent drop at Freeport McMoRan’s (NYSE:FCX) Cerro Verde, the largest copper mine in Peru. According to data from MDO, Cerro Verde produced 1.94 million metric tons of copper concentrate in 2023. Freeport McMoRan indicated in its Q1 2024 report that declines in its South American operations were due to lower volumes of stockpiled leach ore and lower milling rates associated with maintenance.

Other significant copper operations in Peru include Anglo American’s Quellaveco mine and Southern Copper’s (NYSE:SCCO) Tia Maria mine. The majority of copper produced in Peru is shipped to China and Japan, and South Korea and Germany are other top export destinations.

4. China

Copper production: 1.8 million metric tons

In 2024, China produced 1.8 million metric tons of copper. The total was marginally lower than the 1.82 million metric tons produced in 2023, but also marks a steady decline over the past few years, seeing production slip from a recent high of 1.91 million metric tons in 2021.

However, when it comes to refined copper production, China is by far the winner. In 2024, its refined copper production totaled 12 million metric tons, representing more than 44 percent of global refined copper production and six times the production of Chile, the next-top refinery producer. China also holds the world’s highest copper reserves at 190 million MT.

Zijin Mining Group, a leading metal producer in China, owns the Qulong copper-molybdenum-silver-gold mine in Tibet. The company purchased a 50.1 interest in the owner of the Qulong mine in 2024 and is working to consolidate 100 percent ownership. Zijin increased its mine production in 2024 and it is now the largest copper mine in China.

According to MDO, the Qulong mine produced 340 million pounds of copper in 2023. While its 2024 copper production is still being finalized, it is estimated to have increased to 366 million pounds.

5. Indonesia

Copper production: 1.1 million metric tons

In 2024, Indonesia produced 1.1 million metric tons of copper, passing the United States and Russia to become the fifth highest copper producer. The country’s copper production has increased steadily in recent years, and is up significantly from 907,000 MT in 2023 and 731,000 MT in 2021.

Freeport McMoRan’s Grasberg complex is the country’s largest copper mine. According to MDO data, the mine produced 1.66 billion pounds of copper in 2023.

Another of the country’s largest operations is PT Amman Mineral’s (IDX:AMMN,FWB:U4Z) Batu Hijau mine. While production in 2023 was modest compared to Grasberg at 542 million pounds of copper concentrate, it’s estimated that 2024 will see production increase significantly to 1.84 billion pounds as the mine begins processing high-grade ore from its Phase 7 cutback.

In mid-2024, Amman Minerals commissioned a smelting facility that will process 900,000 metric tons of copper concentrate annually to produce 222,000 MT of copper cathodes and 830,000 MT of sulfuric acid.

6. United States

Copper production: 1.1 million metric tons

The United States produced 1.1 million metric tons of copper in 2024. While only 30,000 metric tons less than its 2023 production totals, the country’s 2024 output was a sharp decline from the 1.23 million MT it produced in 2022.

The majority of US copper comes from Arizona, which accounts for 70 percent of domestic supply. Other states with significant copper output include Michigan, Missouri, Montana, Nevada and New Mexico. Overall, 17 mines are responsible for 99 percent of copper production in the United States.

Freeport McMoRan’s Morenci mine in Arizona, a joint venture with Sumitomo (TSE:8053), is the largest copper mine in the US. According to MDO data, the mine produced 700 million pounds of copper metal in 2024 and has 12.63 million pounds of proven and probable reserves.

Other significant operations include Freeport McMoRan’s Safford and Sierrita mines, at which copper production totaled 249 million MT and 165 million MT respectively.

7. Russia

Copper production: 930,000 metric tons

Russia produced 930,000 metric tons of copper in 2024, a sizable increase from the 890,000 MT produced the previous year.

One of the key contributions to the rise in Russian copper output is the ramp-up in Phase 1 production at Udokan Copper’s Udokan mine in Siberia. Although the mine experienced multiple fires at the very end of 2023, copper production was reported to be unaffected. The mine was expected to produce up to 135,000 metric tons of copper in 2024. This is expected to grow to 450,000 MT once Phase 2 comes online in 2028.

8. Australia

Copper production: 800,000 metric tons

In 2024, Australia produced 800,000 metric tons of copper, a slight increase from the 778,000 MT produced in 2023.

The country’s largest copper operation is BHP’s Olympic Dam mine in South Australia. According to MDO data, 2024 marked a 10 year high in total copper production for Olympic Dam at 216,000 metric tons.

The state of Queensland is home to the Mount Isa complex, run by a subsidiary of Glencore. While it is one of Australia’s largest copper producers, the operations will be closed in the second half of 2025.

Australia may have modest output compared to those at the top of the list, but it is tied with Peru for the second highest copper reserves in the world at 100 million metric tons, behind only China with 190 million metric tons.

9. Kazakhstan

Copper production: 740,000 metric tons

In 2024, Kazakhstan produced 740,000 metric tons of copper, on par with 2023’s production totals. Although its production was unchanged year-over-year, the country entered the top 10 copper producers list this year, leapfrogging over Mexico and Zambia.

Kazakhstan’s copper output is up substantially compared to just a few years ago, with the country producing just 510,000 MT in 2021.

The nation plans to continue that trend, releasing a National Development Plan in February 2024 that aims to increase mineral production by 40 percent by 2029. The plan will involve increased exploration, project co-financing and tax incentives for investment.

Among the country’s largest mining companies is private firm KAZ Minerals, which owns the Aktogay mine. According to the company’s Q4 2024 production report, the mine produced 228,800 metric tons of copper during the year, a decline from the 252,400 MT produced in 2023.

10. Mexico

Copper production: 700,000 metric tons

Rounding out our list of top copper producers, Mexico produced 700,000 metric tons of copper in 2024, just 1,000 MT above its 2023 output.

The Buenavista del Cobre mine in Sonora, owned by Grupo Mexico (BMV:GMEXICOB), is the largest copper mine in the country. According to MDO data, the mine produced 725 million pounds of copper concentrate and 193 million pounds of copper cathode in 2023.

In addition, Grupo Mexico also owns Mexico’s second-largest copper mine, La Caridad, which produced 387,000 MT of copper concentrate and 51 million pounds of copper cathode in 2023.

Securities Disclosure: I, Dean Belder, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

Stem cell research and regenerative medicine are growing markets in the life science sector, and the top stem cell companies are working hard to make advancements that can help patients.

Stem cells serve as an internal repair system in the body. They can divide without limit to replenish other cells as long as the body is still alive. Unsurprisingly, there’s a lot of promise for medical advancements, and there are already stem cell treatments approved by the US Food and Drug Administration (FDA). Still, there is a lot of room for further advancements, and plenty of lab work still needs to be done before stem cell products can be used as cell-based therapies or regenerative medicines.

A report from Grand View Research projects that the global stem cell market will reach US$28.89 billion by 2030. The research firm sees “the rising number of stem cell banks, growing focus on increasing therapeutic potential of these, and extensive research for the development of regenerative medicines” as drivers of this market. The stem cell market and the value of regenerative medicine stocks is expected to grow further via increased government funding for cancer research and the development of cellular therapies to treat various cancers.

Grand View Research reports that in 2024 the pharmaceutical and biotechnology companies segment captured the largest revenue share for the stem cell therapy market at 54.19 percent.

1. AstraZeneca (NASDAQ:AZN)

Company Profile

Market cap: US$228.3 billion

First on this list of the top NASDAQ stem cell company stocks is multinational pharma and biotech firm AstraZeneca, which also specializes in other therapeutic areas, including oncology, cardiovascular diseases, the respiratory and central nervous systems and pain control.

While it may be the largest company on this list by market cap, the pharma giant has been slower than its peers in staking a position in the cell therapy market. Its particular focus in oncology is the treatment of solid tumors. The company is also looking at stem cell therapies to treat life-threatening chronic kidney disease and liver disease.

AstraZeneca acquired biotech firm Neogene Therapeutics in 2023, bringing the company’s expertise on T-cell receptor therapies into AstraZeneca’s fold.

Its long-term strategy in this area is to develop ‘off-the-shelf’ allogenic CAR-T therapies to increase the availability and accessibility of the treatments.

2. Amgen (NASDAQ:AMGN)

Company Profile

Market cap: US$160.05 billion

A global leader in biotech, Amgen is heavily invested in gene-based research and uses advanced human genetics to develop and manufacture therapeutics targeting a variety of diseases with unmet medical needs.

The biotech firm has a multi-year fund agreement with Canada’s Center for Commercialization of Regenerative Medicine (CCRM), which specializes in developing and commercializing regenerative medicine-based technologies and cell and gene therapies. Under the multi-year agreement, both CCRM and Amgen will fund early stage regenerative medicine-based technologies and therapies with research conducted in institutions that are part of CCRM’s global network.

In May 2024, the US FDA approved Amgen’s Imdelltra for the treatment of adult patients with extensive-stage small cell lung cancer, making the drug the first and only T-cell engager therapy available for treating this condition. The therapy activates the patient’s own T cells to attack particular tumor cells.

3. Gilead Sciences (NASDAQ:GILD)

Company Profile

Market cap: US$137.13 billion

Global biopharmaceutical company Gilead Sciences specializes in developing breakthrough medicines to prevent and treat serious diseases such as HIV, viral hepatitis and cancer.

One of the stem cell therapies in its product portfolio is Yescarta, a CAR-T cell therapy for blood cancer and the first such therapy for certain types of non-Hodgkin’s lymphoma. Yescarta aids a patient’s immune system in fighting the disease. Gilead currently has at least eight cell therapy candidates in its product pipeline, including three in Phase 3 clinical studies targeting high-risk lymphomas and myeloma.

4. Sanofi (NASDAQ:SNY)

Company Profile

Market cap: US$134.81 billion

French multinational pharmaceutical company Sanofi develops therapeutic products for diabetes and cardiovascular diseases, oncology, immunology, multiple sclerosis, rare diseases, rare blood disorders and vaccines. Its product portfolio includes Mozobil, a hematopoietic stem cell mobilizer that helps bone marrow release stem cells into the bloodstream for transplant into the body.

In 2021, the firm bolstered its regenerative medicine business through the US$1.9 billion acquisition of Kadmon, adding FDA-approved stem cell transplant product Rezurock to its portfolio. Sanofi has since partnered with privately held biotech company Scribe Therapeutics to develop CRISPR-based cell therapies targeting cancers.

The company also has a licensing agreement with Innate Pharma (NASDAQ:IPHA) as the two companies collaborate on developing natural killer cell therapeutics in oncology. One investigational drug candidate under this collaboration is SAR’579, which is in Phase 1/2 studies for the treatment of blood cancers with high unmet needs, including relapsed or refractory acute myeloid leukemia, B cell acute lymphoblastic leukemia and high-risk myelodysplasia. SAR’579 received FDA Fast Track Designation for the treatment of acute myeloid leukemia.

5. Vertex Pharmaceuticals (NASDAQ:VRTX)

Company Profile

Market cap: US$123.34 billion

Vertex Pharmaceuticals has developed a number of approved treatments for cystic fibrosis, and has a pipeline of genetic and cell therapies for diseases such as sickle cell disease, beta thalassemia, Duchenne muscular dystrophy and type 1 diabetes.

Vertex and its partner CRISPR Therapeutics (NASDAQ:CRSP) co-developed drug Casgevy, a CRISPR/Cas9 genome-edited cell therapy, received FDA approval in December 2023 for the treatment of sickle cell disease in patients 12 years and older with recurrent vaso-occlusive crises. Casgevy is the first ever treatment based on CRISPR technology to be approved for the US market. In 2024, the drug received validation from the European Medicines Agency and Health Canada for this indication as well.

In addition, Vertex has two active clinical trials for type 1 diabetes cell therapy: X-880, an investigational allogeneic stem cell-derived, insulin-producing islet cell therapy in Phase 1/2/3 clinical trials; and VX-264, designed to be a surgically implanted device in phase 1/2 clinical trials.

6. BioNTech (NASDAQ:BNTX)

Company Profile

Market cap: US$28.67 billion

Immunotherapy company BioNTech is advancing novel therapies for diseases such as cancer. The company combines computational discovery and therapeutic drug platforms to rapidly develop new biopharmaceutical products. The company is best known today for its mRNA vaccine development and in-house manufacturing capabilities, as well as its COVID-19 vaccine, created with partner Pfizer (NYSE:PFE).

BioNTech is engaged in collaborative partnerships aimed at assembling mRNA vaccine candidates for a range of infectious diseases. BioNTech’s portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, CAR-T cell therapies, bispecific checkpoint immuno-modulators, targeted cancer antibodies and small molecules.

The most advanced of its CAR-T product candidates is BNT211, which comprises two drug products designed to induce an immune response against various CLDN6-positive solid tumors, such as ovarian cancer, sarcoma, testicular cancer, endometrial cancer and gastric cancer. BNT211 is in a Phase 1 trial in patients with CLDN6-positive relapsed or refractory advanced solid tumors.

7. BeiGene (NASDAQ:ONC)

Company Profile

Market cap: US$26.72 billion

Biotechnology company BeiGene specializes in the development of drugs for cancer treatment across a broad range of areas, including esophageal squamous cell carcinoma, non-small cell lung cancer, mantle cell lymphoma, non-Hodgkin’s lymphoma and ovarian cancer. Its clinical development pipeline includes 12 advanced Phase 3 programs.

BeiGene has a strategic partnership with Shoreline Biosciences for the development and commercialization of a genetically engineered natural killer cell therapy.

BeiGene’s bruton tyrosine kinase inhibitor Brukinsa gained FDA approval in early 2023 for patients with chronic lymphocytic leukemia or small lymphocytic leukemia, both forms of non-Hodgkin’s lymphoma.

The company’s monoclonal antibody Tevimbra garnered FDA approval in early 2024 for the treatment of advanced or metastatic esophageal squamous cell carcinoma after prior chemotherapy. Near the end of the year, the European Commission gave the green light to the drug for first-line treatment of advanced/metastatic esophageal squamous cell carcinoma and gastric or gastroesophageal junction cancer, while the FDA approved it for first-line treatment of gastric and gastroesophageal junction cancers in combination with chemotherapy.

8. BioMarin Pharmaceutical (NASDAQ:BMRN)

Company Profile

Market cap: US$13.1 billion

BioMarin Pharmaceutical develops and commercializes therapies for patients with serious, life-threatening genetic diseases and medical conditions.

The global biotech company focuses on diseases with critical unmet medical needs, as well as products with an opportunity to be first to market or to offer significant benefits over existing products. BioMarin’s portfolio includes eight commercial products and multiple clinical and preclinical product candidates across its therapeutic areas.

9. Moderna (NASDAQ:MRNA)

Company Profile

Market cap: US$12.98 billion

Biotechnology and pharmaceutical company Moderna is a pioneer in the field of mRNA. The company’s assets include a diverse clinical portfolio of vaccines and therapeutics, plus a large intellectual property portfolio in areas such as mRNA and lipid nanoparticle formulation; it also has an integrated manufacturing plant that allows for both clinical and commercial production.

These assets, along with Moderna’s network of domestic and overseas government and commercial collaborators, allowed for the rapid development of one of the world’s most effective COVID-19 vaccines.

The other therapeutics and vaccines in the company’s pipeline are targeting infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and autoimmune diseases. Moderna has 23 development programs underway across these areas.

10. Bio-Techne (NASDAQ:TECH)

Company Profile

Market cap: US$10.3 billion

Bio-Techne develops, manufactures and sells reagents, diagnostic instruments and bioprocessing services for research and clinical applications, including drug discovery. The company’s revenue segments include diagnostics and spatial biology, and protein sciences.

Bio-Techne offers tailored technologies and services for its life science customers developing and producing immune cell, regenerative and gene therapies. The company expanded its Advanced Cell Diagnostics branded RNAscope probe portfolio in February 2025.

‘With over 12,000 citations in clinical and translational research combined, our expanded portfolio of gold-standard RNAscope probes enables customers to accelerate biomarker validation and ultimately improve lives,’ said Dr. Matt McManus, president of Bio-Techne’s diagnostics and spatial biology segment.

FAQs for stem cell stocks

What are stem cells?

Stem cells are the building blocks of life, with special capabilities that are particularly important in both the early and later stages of a human’s lifecycle. Human stem cells have the ability to develop into a variety of different cell types in the body, including organ-specific cells, as well as muscle tissue and bone marrow cells; they can even renew themselves.

What is stem cell therapy?

Stem cell therapy is the use of stem cells to treat or prevent a disease or condition, including some cancers such as leukemia, lymphoma, multiple myeloma and neuroblastoma. Cell therapy involves the direct administration of cells into the body to promote the body’s natural ability to heal itself.

What is stem cell banking?

Stem cell banking is the process of collecting, processing and cryogenically storing potentially life-saving stem cells for future use in therapies and regenerative medicine.

Securities Disclosure: I, Melissa Pistilli, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

China’s military has set up a zone for “live-fire training” about 46 miles (74 kilometers) off the southwestern coast of Taiwan without advance notice, the island’s defense ministry said on Wednesday.

It comes a day after Taiwan’s coast guard detained a Chinese-crewed cargo ship suspected of cutting an undersea cable in the Taiwan Strait.

Taiwan’s defense ministry said it detected 32 Chinese military aircraft in the Taiwan Strait starting shortly before 9am on Wednesday (7.42 p.m. Tuesday ET). It added that 22 of those aircraft flew near the north and southwest of the island and carried out a “joint combat readiness patrol” with Chinese warships, according to the statement.

“During this period, (China) blatantly violated international norms by unilaterally designating a drill zone approximately 40 nautical miles off the coast of Kaohsiung and Pingtung without prior warning, claiming it would conduct ‘live-fire training,’” the ministry said.

There was no immediate comment from Beijing on the Taiwan statement. China’s Foreign Ministry did not comment on it when asked at a regular news conference Wednesday, saying it’s “not a diplomatic issue.”

China’s ruling Communist Party claims Taiwan as its territory, despite having never controlled it, and has vowed to take the self-governing democracy by force if necessary. Under Chinese leader Xi Jinping, Beijing has significantly ramped up military, diplomatic and economic pressure on Taiwan.

Kaohsiung, a strategic commercial hub for Taiwan, is home to the island’s largest and busiest port.

Taiwan’s defense ministry said China declared the drill zone within international shipping lanes via temporary radio broadcasts, posing “a severe threat to the safety of international aviation and maritime navigation.”

“This is a blatant provocation against regional security and stability,” the ministry added.

This post appeared first on cnn.com

The parents of an 8-year-old girl who died after they withheld her insulin, encouraged by members of a small Christian sect who believed God would save her, have been sentenced to at least 14 years in prison.

Elizabeth Struhs died in January 2022 on a mattress on the floor of her home in Toowoomba, west of Brisbane, five days after her father Jason Struhs, 53, declared that she no longer needed medication for Type 1 diabetes.

Her mother, Kerrie Struhs, 49, encouraged Elizabeth’s father to withhold her insulin, as did 12 other members of a Bible-based sect known as “The Saints,” who were also found guilty of manslaughter.

Sect leader Brendan Stevens, 63, was handed a prison sentence of 13 years by Justice Martin Burns in the Queensland Supreme Court on Wednesday. Eleven other members of the sect, who sang and prayed while Elizabeth died, were also due to be sentenced.

It’s not the first time Jason and Kerrie Struhs have been prosecuted for failing to give Elizabeth medical care.

In 2019, Elizabeth, then 6, was hospitalized for a month after becoming gravely ill from undiagnosed and untreated diabetes. At the time, her father rejected the sect’s insistence that God would heal her and eventually took his daughter to hospital.

That time, Jason Struhs pleaded guilty to “failing to provide the necessaries of life to Elizabeth” and was given a suspended sentence after testifying against his wife. Kerrie Struhs pleaded not guilty and was given an 18-month sentence.

What happened next all but sealed Elizabeth’s fate.

While Kerrie Struhs was in prison, her husband’s 17-year opposition to the sect crumbled, the trial heard, and he became “baptized” as its newest member.

Elizabeth died just three weeks after her mother was released from prison on parole, telling her parole officer that she’d withhold her daughter’s treatment again, if given the choice. She also said she wouldn’t intervene if anyone tried to help Elizabeth – but no one did.

A ‘miracle’ recruit

The couple at the center of the case had a long and often combative relationship.

Jason Struhs told police that his wife wasn’t very religious during the first few years of their marriage, but that changed when she met sect leader Brendan Stevens and his wife Loretta in 2004.

As Kerrie Struhs grew closer to the Stevens family, she began to reject medical treatment. Jason Struhs remained a staunch non-believer, who insisted that their eight children be vaccinated.

The couple’s conflicting beliefs caused friction in the household, and for a time Jason moved to the garage to “escape the tension.” He worked night shifts and preferred to stay away from the house, either working or playing golf, he told police, according to court documents.

Kerrie Struhs told police her husband was an “angry man” who didn’t believe in God, and that she was planning to leave him after her release from prison in December 2021.

But she changed her mind after she discovered that Jason had joined the church, describing him as much calmer, like a “new person.”

“The change in him has been unbelievable,” she told police.

Jason Struhs told police he had a “mental breakdown” after Kerrie went to prison and sought support from sect members.

To the church, the conversion of someone once vehemently opposed to their teachings was something of a “miracle” – proof that God had cured his anger.

A small home-based sect

When Jason Struhs declared in early January 2022 – just five months after joining the sect – that Elizabeth no longer needed insulin, church members were elated.

Their campaign to convince him that Elizabeth could be cured by God had worked.

Within days her condition deteriorated, and even as she lay dying with the insulin in the cupboard, no one gave it to her or suggested they seek medical help.

As Elizabeth became sicker, vomiting then unresponsive, Jason Struhs seemed to waver in his conviction, but church members rallied around him, encouraging him to follow God’s will.

They sat at Elizabeth’s bedside, singing and praying. “Whatever the Lord’s plan is for us, we will follow it,” Stevens later told police.

Elizabeth died on January 7, 2022, of diabetic ketoacidosis, a complication caused by a lack of insulin and medical treatment for diabetes – the same condition she had in 2019.

The sect continued to sing, dance and pray around her body for 36 hours before Jason Struhs said it was time to phone police.

For years, the sect’s beliefs were reinforced by their leader, Brendan Stevens, who taught his followers to reject modern medicine but denied any responsibility for Elizabeth’s death.

In 2022, as Elizabeth’s condition deteriorated, Stevens told her parents, “This is just a little trial to prove that you all are truly faithful to our faithful God,” according to court documents.

Stevens’ wife Loretta, 67, and six of their adult children – Therese, Andrea, Acacia, Camellia, Alexander and Sebastian Stevens, ages 24 to 35, were also convicted, along with Elizabeth’s older brother Zachary Struhs, 22.

The others included Lachlan and Samantha Schoenfisch, a married couple aged 34 and 26, and Keita Martin, 24, who went to school with the Stevens children and moved in with the family when she was 17. During the trial, their family members told the court they’d become increasingly concerned about their extreme religious beliefs.

But not all were taken in by Brendan Stevens.

Jayde Struhs, Jason and Kerrie Struhs’ eldest daughter, gave evidence against her parents. She left their home at age 16 for fear she’d never be accepted as gay.

In a victim impact statement read in court, Jayde Struhs said: “These people only wanted to control my family and everything they did. All for the sense of power … so they could play God.”

All 14 defendants represented themselves during a 9-week judge-only trial in 2024, however none gave or called any evidence. Speaking on their behalf, Brendan Stevens called the trial a “religious persecution.”

Jayde Struhs told Australia’s national broadcaster, the ABC, that Stevens instilled an Armageddon-style fear in his followers.

“The main … messaging that Brendan puts out there is that the world’s going to end and Jesus is going to come back and save us … if you’re not absolute in the walk of God, you’ll go to hell forever,” she said.

Cult expert Raphael Aron, director of Cult Consulting Australia, says Jason Struhs would have been under “immense” pressure to join the group and follow their beliefs.

He said prison is unlikely to change the beliefs of “The Saints,” and if members are allowed further contact with each other, it could further entrench their ideology.

“I don’t know if any group has fallen apart because the leader went to jail; he’s just seen as a martyr, basically a replica of Jesus on the cross,” said Aron. “There’s all sorts of other ways of justifying it, and they keep going.”

He said he hopes Elizabeth’s death acts as a “wake up call” to anyone who may be questioning the legitimacy of people influencing themselves or a loved one.

A major red flag is the rejection of conventional medicine, Aron said, as it allows the group to conceal abusive behavior.

“The one area in life where the groups can actually be held accountable will be through the medical world, because that practitioner has a responsibility to do something about what’s going on,” said Aron.

Sect leaders also often ban members from accessing the internet because if they did, they might find damning testimony from former members, he added.

Small groups with extreme beliefs are all but impossible to detect unless people come forward, Aron said – but in Australia, unlike the United States, there are few avenues to report them.

He’s advocating for a regulatory body with the power to investigate complaints.

“The problem is, if you go to the police and no crime has been committed, they can’t do anything, and by the time the crime has been committed, it’s too late.”

This post appeared first on cnn.com